New drug may curb painful eye flares in arthritis patients

NCT ID NCT07018206

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug upadacitinib can reduce how often people with axial spondyloarthritis (a type of arthritis affecting the spine) get sudden eye inflammation (acute anterior uveitis). About 200 adults who have had at least one eye flare in the past year will take the drug daily for 52 weeks. Researchers will track eye flare rates, arthritis symptoms, pain, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLARTHRITIS (AXSPA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis anterior uveitis Axial Spondyloarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact